SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Sacituzumab tirumotecan
Related studies linked through entity extraction aliases.
Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
- Status
- RECRUITING
- Phase
- PHASE3
Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)
- Status
- RECRUITING
- Phase
- PHASE2
SKB264 Combined With KL-A167 Neoadjuvant Therapy for Early-stage, High-risk ER+/HER2- Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Sacituzumab Tirumotecan in Neoadjuvant Treatment of Early-Stage TNBC
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Status
- RECRUITING
- Phase
- PHASE3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Status
- RECRUITING
- Phase
- PHASE3
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Status
- RECRUITING
- Phase
- PHASE3
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Status
- RECRUITING
- Phase
- PHASE3
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)
- Status
- RECRUITING
- Phase
- PHASE2
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Status
- RECRUITING
- Phase
- PHASE3
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3